Teachers Retirement System of The State of Kentucky Purchases 12,943 Shares of Lantheus Holdings, Inc. $LNTH

Posted by on Jul 15th, 2026

Teachers Retirement System of The State of Kentucky raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 63.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 33,264 shares of the medical equipment provider’s stock after purchasing an additional 12,943 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Lantheus were worth $2,523,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of LNTH. Sovran Advisors LLC bought a new stake in shares of Lantheus during the 1st quarter worth approximately $211,000. Sequoia Financial Advisors LLC bought a new position in Lantheus in the 1st quarter valued at $297,000. Peterson Wealth Services grew its position in Lantheus by 3,160.5% in the 1st quarter. Peterson Wealth Services now owns 6,684 shares of the medical equipment provider’s stock valued at $507,000 after acquiring an additional 6,479 shares during the last quarter. SkyOak Wealth LLC increased its stake in Lantheus by 1.8% in the first quarter. SkyOak Wealth LLC now owns 64,284 shares of the medical equipment provider’s stock worth $4,876,000 after purchasing an additional 1,154 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new stake in Lantheus in the first quarter worth $230,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 2.9%

Shares of NASDAQ LNTH opened at $102.37 on Wednesday. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $101.46 and a two-hundred day simple moving average of $83.53. The firm has a market cap of $6.66 billion, a PE ratio of 24.67 and a beta of -0.06. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.86.

Lantheus (NASDAQ:LNTH – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period in the prior year, the business earned $1.53 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Citizens Jmp reiterated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Finally, Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $108.29.

View Our Latest Report on Lantheus

About Lantheus

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.